18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)-

Request For Quotation

18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)- manufacturers

  • Trk-IN-11
  • Trk-IN-11 pictures
  • $1980.00
  • 2026-05-11
  • CAS:2700265-62-7
  • Purity:
  • Supply Ability: 10g
18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)- Basic information
Product Name:18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)-
Synonyms:Trk-IN-11;18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)-
CAS:2700265-62-7
MF:C21H22FN5O3
MW:411.43
EINECS:
Product Categories:
Mol File:2700265-62-7.mol
18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)- Structure
18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)- Chemical Properties
density 1.47±0.1 g/cm3(Predicted)
pka10.65±0.60(Predicted)
Safety Information
MSDS Information
18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)- Usage And Synthesis
UsesTrk-IN-11 (Compound 14h) is a potent inhibitor of TRK (IC50 = 1.4, 1.8 nM, against TrkA, TrkAG595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease[1].
IC 50TrkA
References[1] Fan Y, et al. Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: Design, synthesis and biological evaluation. Bioorg Med Chem Lett. 2022;63:128646. DOI:10.1016/j.bmcl.2022.128646
18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)- Preparation Products And Raw materials
Tag:18,1-Metheno-6H-[1,4]oxazino[3,4-i]pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-15(12H)-one, 9-fluoro-3,4,13,14-tetrahydro-4,13,13-trimethyl-, (4R)-(2700265-62-7) Related Product Information
Tanezumab Amitriptyline GW441756 HIOC N-Acetyl-5-hydroxytryptamine NSI-189